Johnson & Johnson (NYSE:JNJ) Q4 2022 Earnings Call Transcript

Joaquin Duato: So, regarding the main data readouts that you could expect in 2023, I mean, I commented already on CARTITUDE-4, which is a key one for us. Again, this is an event-driven study, so it’s difficult for us to give you exact timing, Louise. Importantly, we have the potential for an interim analysis on the Mariposa study, which is the study of RYBREVANT plus lazertinib in frontline non-small cell lung cancer with EGFR mutations in this study versus Tagrisso. And this is an important study for us. And also, we have the potential clinical data from the PAPILLON study, which is in frontline non-small cell lung cancer in combination with chemotherapy. So, those are important ones in non-small cell lung cancer. And then, staying in oncology, we also have the data for the — from the Phase 2 SunRISe-1 study of our TAR-200 platform, our drug-eluting device in non-muscle invasive bladder cancer.

And we continue to work on our high-risk localized prostate cancer with ERLEADA. So, that’s key elements in our oncology side. As far as nipocalimab, we are expecting data from our Phase 3 studies in RA, in rheumatoid arthritis, which I know has created significant attention from you and also in hemolytic disease of the fetus and the newborn. It will be towards the later part of the year. That’s when you can expect those data to come up. And then, keeping with important date targets next year, we’ll also have the data reads in our 2 IBD studies, ulcerative colitis and Crohn’s disease with TREMFYA. Finally, important progress in our pipeline is that we will be starting our Phase 3 clinical program with milvexian, our Factor XI anticoagulant with our partners at Bristol-Myers Squibb.

So, I would say, a very important year for us in terms of data read. That will also include our Phase 2 study of our oral IL-23. It’s difficult for us to give you an exact time line, but we fully expect that to happen in 2023. So, many important data reads for us that will showcase the good execution that we’re having in our pipeline.

Jessica Moore: Thank you, Louise, and thanks to everyone for your questions and your continued interest in our company. We apologize to those that we couldn’t get to because of time, but don’t hesitate to reach out to the Investor Relations team with any questions that you may have. I would now like to turn it over to Joaquin for some brief closing remarks.

Joaquin Duato: So thank you, everyone, for your questions and interest in Johnson & Johnson. While we have highlighted some of the challenges that we have in the macro environment, we think that 2023 is going to be another exciting year for innovation, for patients. And you can rely on us on delivering strong financial performance for both, the near and the long term. Thank you very much.

Operator: This concludes today’s Johnson & Johnson’s fourth quarter 2022 earnings conference call. You may now disconnect.